Western Standard LLC’s Belite Bio BLTE Stock Holding History

Western Standard LLC’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-60,026	Closed	-$9.6M	–	24
2025 Q4	$9.6M	Buy	+60,026	New	+$7.11M	4.43%	8

Other funds holding BLTE

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Western Standard LLC's BLTE Position: Q1 2026 in Review

Western Standard LLC sold out of Belite Bio (BLTE) in Q1 2026, closing a stake of 60,026 shares — an estimated $9.6M sold.

Western Standard LLC first reported a position in BLTE in Q4 2025 and held it in 1 quarter. The position peaked at $9.6M in Q4 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

Western Standard LLC reported no remaining Belite Bio position as of Q1 2026 after selling out during the quarter.
Western Standard LLC sold 60,026 Belite Bio shares in Q1 2026, an estimated $9.6M.
Western Standard LLC first reported a position in Belite Bio in Q4 2025 and held it in 1 quarter.
Western Standard LLC's Belite Bio position peaked at $9.6M in Q4 2025.
75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Western Standard LLC's 13F filing for Q1 2026, filed 5 May 2026.